CNS Flashcards
carbamazepine
use-dependent Na-block;
often first line (generalised)
SEs: rash, dizzy, double vision, blood disorders, autoinduction/interaction, birth defects
sodium valproate
^GABA + sodium blockage; f irst line (Generalised), second line (absence)
SEs: weight gain, tremor, sedation, TFTs, leucopenia, thrombocytopenia; birth defects, liver damage
phenytoin
sodium channels; zero-order (variable response ) and narrow TI; rarely used
good for acute (i.e. stop fits)
SEs: gum growth, nystagmus, BG (rare); birth defects
lamotragine
sodium channels and decreased glutamate; non-sedating; first line (generalised, pregnancy), second line (absence)
SEs: blood and skin disorders, BM toxicity (warn about ‘flu’ and/or rash);
BZD
bind subunits of GABA receptors on Cl channels » increased GABA;
good for status;
SEs: skill and motor; low tolerance and dependence;
Anti-epileptic precautions
preggo: teratogens; lowest dose possible for shortest time (prevention better than seizures)
- first = all or nothing (14d) and organ development issues (10w); greatest risk
- second = CNS (NTD with C, V, P) and general growth
- third = more predictable; post-birth effects; give folate and vitamin K (T3)
- liver enzyme inducers » interactions e.g. affect warfarin (Decreased activity)
- monitor: LFTs, INR (C, V), FBC (aplastic anaemia (L), Tpenia (V)
SSRI
5HT; first lines (tolerance and safety in OD);
morning dose;
bleeding risk, epilepsy caution, interactions
TCA
NA and 5HT (also mACh-R and histamine); antimuscarinic SEs, sedating (night dose); also used in neuropathic pain, migraine, IBS
SEs: dry mouth, sedation, blurred vision, constipation, urinary retention; OD risk
NARI (reboxetine)
selective; used if SSRI-resistant and unable to take TCA
SNRI (venlafaxine)
5HT and NA; non-sedating + no antimusc effect but withdrawal risk;
caution DM/IHD
SEs: hypertension, GI
NaSSAs (mirtazepine)
NA and 5HT; limited antimusc effect, but weight gain and sedation
MAOI
block breakdown (NA, 5HT, Dopamine);
diet and drug interactions (cheese reaction and Hypertensive crisis - catecholamines)
Management of depression
if mild, watch and wait (2/52); CBT; not pharma to start
other non-pharma: sleep hygiene and ECT
if started on pharma: first-line SSRI (TCA if sleep issues)
review after 2 wk: poor response = increase/switch
review 2-4w for 3m, then less regularly if good response
remission >6m (2y if 2 episodes) » ?Withdrawal (gradual dose/freq, approx 4w); dizzy, flue, dd and nausea, paraesthesia, anxiety, headache
Management of epilepsy
TONIC-CLONIC: carbamazepine, lamotrigine, sodium valproate
ABSENCE: ethosuximide; sodium valproate, lamotrigine second line
MYOCLONIC: sodium valproate, clonazepam, levetiracetam
ATYPICAL ABSENCE/ATONIC/TONIC: sodium valproate, lamotrigine, clonazepam
MONITOR: blood (leucopenia), liver, skin
management of anxiety
BB: SANS SEs; symptom relief
BZD: ^GABA; decreased anxiety and aggression, increased sleep;
AD: many help in panic attacks (anxiolytics); better long-term
buspirone: 5HT (and DA) activation; 2-3w delay, no sedation, no panic help; dizzy, nausea, headach